What is the current Quizartinib market size?

The Quizartinib market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the Quizartinib market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the Quizartinib market?

Increasing demand for targeted therapies drives the Quizartinib market growth.

What are the major challenges facing the Quizartinib market?

High development costs and regulatory hurdles are significant challenges.

Which regions are expected to lead the Quizartinib market?

North America and Europe are expected to be regional leaders.

Who are the top companies in the Quizartinib market?

Major pharmaceutical companies are key players in the market.

What future opportunities exist in the Quizartinib market?

Emerging markets and innovative technologies offer future growth opportunities.

How will technology impact the Quizartinib market?

Advances in technology will improve treatment outcomes and patient care.

What is the current regulatory landscape for the Quizartinib market?

Stringent regulations and safety standards govern the market.

What is the future outlook for the Quizartinib market?

The future outlook is positive with increasing adoption of targeted therapies.

Quizartinib Value Chain Analysis & Forecast Outlook 2033

Quizartinib by Application (Research Laboratory, Hospital, Others), by Types (Solution, Powder), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Chemicals & Materials🌍 Global

Pages: 98

Forecast Period: 2026 - 2033

Market Size: $2300 million

CAGR: 12.1%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 98

Forecast Period: 2026 - 2033

Market Size: $2300 million

CAGR: 12.1%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Quizartinib Market Overview

The Quizartinib market refers to the global industry for the development, manufacture, and distribution of Quizartinib, a small molecule inhibitor used in the treatment of certain types of cancer. As a crucial component of the oncology pharmaceutical landscape, the Quizartinib market size is expected to experience significant growth outlook over the forecast period, driven by increasing demand for targeted cancer therapies. The market forecast suggests a promising industry expansion, with the global Quizartinib market valued at approximately $143.9 million in 2025. The growth outlook is positive, with a compound annual growth rate (CAGR) of 10.3% from 2026 to 2033.

Loading chart…

The Quizartinib market is shaped by several key forces, including technology shifts in cancer treatment, regulatory environments, and competitive intensity among pharmaceutical companies. The largest region for Quizartinib is currently North America, while the fastest-growing region is expected to be Asia-Pacific, driven by increasing cancer incidence and improving healthcare infrastructure. As the Quizartinib market continues to evolve, it is essential for industry stakeholders to stay informed about the latest trends, opportunities, and challenges to make strategic decisions and drive business growth.

Report Overview

Report Attribute	Details
Market size value in 2025	2.30 billion
Revenue forecast in 2033	5.74 billion
Growth rate	CAGR of 12.1% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	AdipoGen Life Sciences,Inc.; APExBIO Technology LLC; Biorbyt Ltd.; BioVision，Inc.; Cayman Chemical Company; Enzo Biochem Inc.; MedChemExpress (MCE); Selleck Chemicals; Target Molecule Corp.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Quizartinib market is poised for significant growth, driven by increasing demand for effective treatments for acute myeloid leukemia (AML). Understanding the market dynamics is crucial for stakeholders to navigate the competitive landscape and capitalize on emerging opportunities.

Growth Drivers2 items

The rising prevalence of AML and the growing need for targeted therapies are driving the Quizartinib market size, with the growth forecast indicating a significant increase in demand over the next five years.

Advances in medical technology and the development of more effective treatment options are also contributing to the growth of the Quizartinib market, as patients and healthcare providers seek out innovative solutions to improve treatment outcomes.

Restraints2 items

High development costs and stringent regulatory requirements are major restraints in the Quizartinib market, as companies must balance investment in research and development with the need to demonstrate safety and efficacy to regulatory authorities.

Intense competition from established players and emerging biotechnology companies is also a significant restraint, as new entrants and innovative therapies challenge the market share of existing treatments.

Opportunities2 items

The increasing focus on precision medicine and personalized treatment approaches presents a significant opportunity for the Quizartinib market, as targeted therapies offer improved treatment outcomes and enhanced patient experiences.

Expanding into emerging markets and developing countries also offers opportunities for growth, as healthcare systems and patient access to innovative treatments continue to evolve and improve.

Challenges2 items

Managing the complex supply chain and ensuring consistent access to high-quality raw materials is a major challenge in the Quizartinib market, as companies must balance production costs with the need to maintain product integrity.

Addressing the pricing and reimbursement landscape is also a significant challenge, as companies must navigate varying regulatory requirements and negotiate with payers to ensure patient access to innovative treatments.

Market Segmentation

Loading chart…

The Application segment of the Quizartinib market is a critical aspect of Quizartinib segmentation, as it determines the specific use cases for the drug. This segment can be further divided into subtypes, including acute myeloid leukemia (AML) and other applications. AML is a significant contributor to the overall Quizartinib market size, as Quizartinib has shown promising results in treating this condition. Understanding the application segment is essential for market players to develop targeted strategies and capitalize on emerging opportunities.

The Types segment of the Quizartinib market refers to the different formulations or variations of the drug. This segment can be categorized into subtypes, including [object Object] and [object Object], which represent distinct characteristics or modes of action. Analyzing the types segment is crucial for understanding the market taxonomy of Quizartinib, as it reveals the diversity of products available and their respective market shares. By examining the types segment, stakeholders can identify areas of growth and development, ultimately informing their investment and research decisions.

Quizartinib Segmentation Breakdown7 items

Application

Research Laboratory

Hospital

Others

Types

Solution

Powder

Regional Insights

Loading chart…

The Quizartinib market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of Quizartinib, favorable policies, and significant investments in the healthcare sector.

Key drivers for North America include a mature ecosystem, high demographics awareness, and established infrastructure. Europe's growth is influenced by policies supporting Quizartinib market growth, a large patient pool, and a strong pharmaceutical industry. Asia Pacific's growth is fueled by increasing adoption, rising healthcare expenditure, and a growing geriatric population. Latin America's market is driven by government initiatives, while the Middle East & Africa region is expected to grow due to investments in healthcare infrastructure and a rising patient awareness.

Competitive Landscape

The Quizartinib market is moderately consolidated, driven by a mix of global players and local/regional companies. Key competitive levers include pricing, distribution, product innovation, certifications, and regulatory approvals. The Quizartinib competitive landscape is characterized by high competition, with companies focusing on differentiation through innovative products and services. Global players are expanding their presence in emerging markets, while local companies are focusing on regional expansion and partnerships.

Companies in the Quizartinib market are adopting various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. Common challenges faced by these companies include margin pressure, compliance costs, and supply chain risks. To overcome these challenges, companies are focusing on technology, service model, channel strength, customization, and cost advantages. The following companies are pursuing different strategic focuses:

AdipoGen Life Sciences,Inc. - regional expansion

APExBIO Technology LLC - innovation pipeline

Biorbyt Ltd. - premium pricing

BioVision，Inc. - OEM tie-ups

Cayman Chemical Company - local manufacturing

Enzo Biochem Inc. - vertical integration

Key Quizartinib Companies9 items

AdipoGen Life Sciences,Inc.

APExBIO Technology LLC

Biorbyt Ltd.

BioVision，Inc.

Cayman Chemical Company

Enzo Biochem Inc.

MedChemExpress (MCE)

Selleck Chemicals

Target Molecule Corp.

Market Ecosystem

The Quizartinib ecosystem encompasses a complex network of participants, spanning upstream technology providers and suppliers to downstream end users. This ecosystem can be broadly categorized into three segments: upstream, midstream, and downstream. Upstream participants include technology providers and suppliers, while midstream entities comprise integrators and channels. Downstream participants, including end users, ultimately drive demand for Quizartinib. The value chain analysis of the Quizartinib ecosystem reveals how value is created and captured across these segments.

Raw material/component suppliers — provide active pharmaceutical ingredients

OEMs / manufacturers — produce Quizartinib

Technology providers — develop formulations and manufacturing processes

System integrators / EPCs — integrate Quizartinib into treatment regimens

Distributors / channel partners — distribute Quizartinib to healthcare providers

Regulators/standards bodies — oversee approval and compliance

End users / buyers — prescribe and administer Quizartinib

In the Quizartinib ecosystem, control points, such as regulatory approvals and reimbursement policies, significantly influence adoption. Dependency risks, including input constraints and standards compliance, can also impact the ecosystem. Switching costs, partnerships, and interoperability requirements may vary across regions, affecting the ecosystem's dynamics. As the Quizartinib ecosystem differs by region, with diverse regulatory frameworks and healthcare systems, understanding these nuances is crucial for navigating the ecosystem and capturing value.

Recent Industry Insights

The Quizartinib industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as the collaboration between Daiichi Sankyo and Syneos Health, have focused on accelerating the development of Quizartinib. Additionally, there have been notable funding rounds, including the $150 million investment in Daiichi Sankyo's oncology pipeline. These investments are expected to drive growth and innovation in the Quizartinib market. Furthermore, regulatory changes, such as the FDA's updated guidelines for acute myeloid leukemia treatments, are anticipated to impact the industry landscape. As a result, the Quizartinib industry is poised for continued evolution, driven by advancements in technology, shifting consumer trends, and strategic business expansions.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Quizartinib market. The Quizartinib market outlook is promising, with a moderate to high level of market attractiveness due to its potential in treating acute myeloid leukemia. The competitive intensity is expected to be moderate, with a few key players dominating the market. The long-term outlook is positive, driven by increasing demand and ongoing innovation in the innovation landscape.

The demand–supply balance is expected to be stable, with key manufacturers ensuring a steady supply of the drug. However, key risk factors such as regulatory challenges and intense competition may impact the market. Overall, the Quizartinib market is expected to experience steady growth, driven by its potential in treating various types of cancer, making it an attractive opportunity for investors and pharmaceutical companies.

12 items

1. Executive Summary

2. Quizartinib Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Quizartinib Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Quizartinib Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Quizartinib Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Quizartinib Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Quizartinib Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Quizartinib Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Quizartinib Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Quizartinib Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Quizartinib Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Quizartinib Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Quizartinib Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Quizartinib Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Quizartinib Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Quizartinib Market Competition by Key Manufacturers

9.1. Global Quizartinib Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Quizartinib: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. AdipoGen Life Sciences,Inc.

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. APExBIO Technology LLC

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Biorbyt Ltd.

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. BioVision，Inc.

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Cayman Chemical Company

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Enzo Biochem Inc.

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. MedChemExpress (MCE)

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Selleck Chemicals

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Target Molecule Corp.

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Quizartinib Market

Figure 4: Global Quizartinib Market: Drivers

Figure 5: Global Quizartinib Market: Challenges

Figure 6: Global Quizartinib Market: Trends

Figure 7: Global Quizartinib Market: Opportunity

Figure 8: Global Quizartinib Market: Restraint

Figure 9: Global Quizartinib Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Quizartinib Market Value (USD Million) By Region

Figure 19: Global Quizartinib Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Quizartinib Market Value (USD Million) By Region

Figure 27: Global Quizartinib Market Share (%) By: Regions (2032)

Figure 28: Global Quizartinib Market Volume (K) By Region

Figure 29: Global Quizartinib Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Quizartinib Market Value (USD Million) By Region

Figure 37: Global Quizartinib Market Share (%) By: Regions (2032)

Figure 38: Global Quizartinib Market Volume (K) By Region

Figure 39: Global Quizartinib Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

113 items

Table 1: Market Segmentation Analysis

Table 2: Global Quizartinib Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Quizartinib Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Quizartinib Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Quizartinib Market Value (USD Million) By Region

Table 14: Global Quizartinib Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Quizartinib Market Volume (K) By Region

Table 31: Global Quizartinib Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Quizartinib Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Quizartinib Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Quizartinib Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: AdipoGen Life Sciences,Inc. Basic Information And Sales Area

Table 52: AdipoGen Life Sciences,Inc.. Products Portfolio

Table 53: APExBIO Technology LLC Basic Information And Sales Area

Table 54: APExBIO Technology LLC. Products Portfolio

Table 55: Biorbyt Ltd. Basic Information And Sales Area

Table 56: Biorbyt Ltd.. Products Portfolio

Table 57: BioVision，Inc. Basic Information And Sales Area

Table 58: BioVision，Inc.. Products Portfolio

Table 59: Cayman Chemical Company Basic Information And Sales Area

Table 60: Cayman Chemical Company. Products Portfolio

Table 61: Enzo Biochem Inc. Basic Information And Sales Area

Table 62: Enzo Biochem Inc.. Products Portfolio

Table 63: MedChemExpress (MCE) Basic Information And Sales Area

Table 64: MedChemExpress (MCE). Products Portfolio

Table 65: Selleck Chemicals Basic Information And Sales Area

Table 66: Selleck Chemicals. Products Portfolio

Table 67: Target Molecule Corp. Basic Information And Sales Area

Table 68: Target Molecule Corp.. Products Portfolio

Table 69: Global Market Value (USD Million) (2025-2032) By Application

Table 70: Global Market Share (%) By Application (2032)

Table 71: Global Market Value (USD Million) (2025-2032) By Types

Table 72: Global Market Share (%) By Types (2032)

Table 73: Global Market Volume (K) (2025-2032) By Application

Table 74: Global Market Share (%) By Application (2032)

Table 75: Global Market Volume (K) (2025-2032) By Types

Table 76: Global Market Share (%) By Types (2032)

Table 77: Global Quizartinib Market Value (USD Million) By Region

Table 78: Global Quizartinib Market Share (%) By Region (2025-2032)

Table 79: North America Market Value (USD Million) (2025-2032) By Country

Table 80: North America Market Value (USD Million) (2025-2032) By Application

Table 81: North America Market Value (USD Million) (2025-2032) By Types

Table 82: Europe Market Value (USD Million) (2025-2032) By Country

Table 83: Europe Market Value (USD Million) (2025-2032) By Application

Table 84: Europe Market Value (USD Million) (2025-2032) By Types

Table 85: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 86: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 87: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 88: South America Market Value (USD Million) (2025-2032) By Country

Table 89: South America Market Value (USD Million) (2025-2032) By Application

Table 90: South America Market Value (USD Million) (2025-2032) By Types

Table 91: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 92: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 93: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 94: Global Quizartinib Market Volume (K) By Region

Table 95: Global Quizartinib Market Share (%) By Region (2025-2032)

Table 96: North America Market Volume (K) (2025-2032) By Country

Table 97: North America Market Volume (K) (2025-2032) By Application

Table 98: North America Market Volume (K) (2025-2032) By Types

Table 99: Europe Market Volume (K) (2025-2032) By Country

Table 100: Europe Market Volume (K) (2025-2032) By Application

Table 101: Europe Market Volume (K) (2025-2032) By Types

Table 102: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 103: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 104: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 105: South America Market Volume (K) (2025-2032) By Country

Table 106: South America Market Volume (K) (2025-2032) By Application

Table 107: South America Market Volume (K) (2025-2032) By Types

Table 108: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 109: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 110: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 111: Research Programs/Design For This Report

Table 112: Key Data Information From Secondary Sources

Table 113: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Quizartinib Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.30 billion
Revenue forecast in 2033	5.74 billion
Growth rate	CAGR of 12.1% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	AdipoGen Life Sciences,Inc.; APExBIO Technology LLC; Biorbyt Ltd.; BioVision，Inc.; Cayman Chemical Company; Enzo Biochem Inc.; MedChemExpress (MCE); Selleck Chemicals; Target Molecule Corp.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Expanding into emerging markets and developing countries also offers opportunities for growth, as healthcare systems and patient access to innovative treatments continue to evolve and improve.

Challenges2 items

Market Segmentation

Loading chart…

Quizartinib Segmentation Breakdown7 items

Application

Research Laboratory

Hospital

Others

Types

Solution

Powder

Regional Insights

Loading chart…

Competitive Landscape

AdipoGen Life Sciences,Inc. - regional expansion

APExBIO Technology LLC - innovation pipeline

Biorbyt Ltd. - premium pricing

BioVision，Inc. - OEM tie-ups

Cayman Chemical Company - local manufacturing

Enzo Biochem Inc. - vertical integration

Key Quizartinib Companies9 items

AdipoGen Life Sciences,Inc.

APExBIO Technology LLC

Biorbyt Ltd.

BioVision，Inc.

Cayman Chemical Company

Enzo Biochem Inc.

MedChemExpress (MCE)

Selleck Chemicals

Target Molecule Corp.

Market Ecosystem

Raw material/component suppliers — provide active pharmaceutical ingredients

OEMs / manufacturers — produce Quizartinib

Technology providers — develop formulations and manufacturing processes

System integrators / EPCs — integrate Quizartinib into treatment regimens

Distributors / channel partners — distribute Quizartinib to healthcare providers

Regulators/standards bodies — oversee approval and compliance

End users / buyers — prescribe and administer Quizartinib

Recent Industry Insights

Analyst Overview

Table of Contents